Patent №
US 9,682,073
Granted
2017-06-20
Filed 2016
Owner
GILROSE PHARMACEUTICALS, LLC
Lab
—
AI components
1
hardware
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
15075375
A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
AI classification
Ownership
GILROSE PHARMACEUTICALS, LLC
assignment · 380660244
Assignors
ROSEMAN, BRUCE, KAPLAN, GILLA
On an employer assignment, the assignors are typically the inventors.